• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Expansion

VC firms back CHF 15.5m series-B extension for Oculis

  • Oscar Geen
  • Oscar Geen
  • 04 January 2019
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Boston-based healthcare investor Tekla Capital Management has led a consortium of new and existing investors to provide Lausanne-based biopharmaceutical company Oculis with a CHF 15.5m series-B funding round extension.

Nan Fung Life Sciences was also a new investor in the round and was joined by unnamed previous backers. Brunnur Ventures, Silfurberg, Bay City Capital, Novartis Venture Fund and Pivotal BioVenture Partners have all previously invested in the business, according to Unquote Data.

The fresh capital will be used to expand the company’s portfolio through strategic in-licensing, and to advance the development of its pipeline of eyedrop treatments for ophthalmic diseases.

Oculis

  • DEAL:

    Expansion

  • VALUE:

    CHF 15.5m

  • LOCATION:

    Lausanne

  • SECTOR:

    Biotechnology

  • FOUNDED:

    2014

The company simultaneously announced its first in-licensing agreement for a topical anti-TNF alpha antibody from Novartis. Proceeds from the funding round were used to finance the agreement but no further financial details were disclosed.

Tekla’s Henry Skinner will join Oculis’ board as non-executive director. Stefan Sveinsson, the former head of R&D at Actavis, will step down from the board; he joined in 2016 following the initial closing of the company’s series-B.

Previous funding
Icelandic investment firms Brunnur and Silfurberg led a series-A funding round for Oculis in 2016.

Bay City Capital led a CHF 20m series-B funding round for the firm in 2017 alongside Novartis Venture Fund, Pivotal BioVenture Partners, Brunnur Ventures and Silfurberg.

Company
Oculis is a clinical-stage biotechnology company focused on the development of topical treatments for ophthalmic diseases, for both back and front of the eye. Headquartered in Lausanne, Switzerland, with research operations in Reykjavik, Iceland, Oculis was founded by Einar Stefánsson and Thorsteinn Loftsson in 2014.

People
Oculis – Riad Sherif (CEO).

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Expansion
  • DACH
  • Healthcare
  • Venture
  • Switzerland

More on Expansion

Wealth managers and financial advisers
Blackstone takes minority stake in Groupe Premium

Deal values French wealth manager at EUR 1.15bn after earlier full exit attempt saw Eurazeo target EUR 1.5bn

  • Expansion
  • 31 July 2023
Risk and compliance management services
e-Attestations aims to triple size with new Keensight backing

Keensight is investing in the risk management platform via its EUR 1bn fifth fund, which closed in 2019

  • Expansion
  • 25 July 2023
Bolt-ons and buy-and-build platforms
The Bolt-Ons Digest - 3 July 2023

Unquote’s selection of the latest add-ons with Palatine's Anthesis, Nordic Capital's Regnology, Waterland's Janssen and more

  • Expansion
  • 03 July 2023
Valentina Vitali of Limerston Capital
GP Profile: Limerston Capital anticipates higher volume but more complex M&A as market steadies

UK-based GP is seeing dealflow driven by carve-outs and buy-and-build in a market where organic multiple arbitrage is no longer a given

  • GPs
  • 07 June 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013